Washington SB5204 mandates a study on ibogaine-assisted therapy for opioid use disorder.

Washington SB5204 requires the University of Washington to conduct a three-year cohort study on ibogaine-assisted therapy for adults with opioid use disorder. The study, to be conducted in a licensed clinic in Mexico, will compare outcomes of ibogaine therapy followed by therapeutic support to standard U.S. treatments. It will measure various outcomes including treatment engagement, reduction in opioid use, and self-efficacy. The study aims to determine if ibogaine offers advantages over current treatments, which often have limited long-term success and high relapse rates.

Washington SB5204 mandates a study on ibogaine-assisted therapy for opioid use disorder.

Washington SB5204 requires the University of Washington to conduct a three-year cohort study on ibogaine-assisted therapy for adults with opioid use disorder. The study, to be conducted in a licensed clinic in Mexico, will compare outcomes of ibogaine therapy followed by therapeutic support to standard U.S. treatments. It will measure various outcomes including treatment engagement, reduction in opioid use, and self-efficacy. The study aims to determine if ibogaine offers advantages over current treatments, which often have limited long-term success and high relapse rates.